Albumin, a single-chain protein of ca. 580 In reactions of albumin with auranofin and tetraacetylthioglucose, cystine was detected as a product, whereas for deacetylated auranofin, thioglucose and glutathione, mixed disulfides with cysteine were produced. These reactions appear to involve reductive deblocking of albumin disulfides via thioldisulfide interchange reactions [3] .
pharmacology of gold drugs used for the treatment of rheumatoid arthritis, carrying ca. 80% of circulating gold in the body.
The primary binding site for Au(I) on albumin is known to be at the sulfur of Cys34 in domain [2] . We have investigated the structural changes induced, in bovine and human albumin by the oral drug auranofin, its deacetylated metabolite, Et3PAuCI, the injectable drug aurothiomalate, and related thiols, using NMR spectroscopy.
In reactions of albumin with auranofin and tetraacetylthioglucose, cystine was detected as a product, whereas for deacetylated auranofin, thioglucose and glutathione, mixed disulfides with cysteine were produced. These reactions appear to involve reductive deblocking of albumin disulfides via thioldisulfide interchange reactions [3] .
The behavior of the His 1 1H NMR resonance of His3 suggests that albumin exists in two distinct structural forms in solution dependent on whether the side-chain of Cys34 is buried or exposed. Modification of Cys34 by gold binding, disulfide formation or other oxidation, switches the conformation to the exposed form [4] . Such a structural change may influence the metabolism of albumin in vivo, as well as its other binding properties.
The buried-exposed conformational switch of Cys34 induced by aurothiomalate shows an interesting ionic strength dependence. In this case the gold -induced switch may require a concomitant anioninduced structural change in the protein. This interdependence may influence the uptake and transport of aurothiomalate by albumin in vivo.
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